PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) RETAINS DONOHOE ADVISORY ASSOCIATES LLC, TO ASSIST IN PREPARING TO SEEK A LISTING ON A NATIONAL SECURITIES EXCHANGE

Salt Lake City, UT- February 27, 2018- Predictive Technology Group, Inc. (OTCPINK:PRED) announces that it has engaged Donohoe Advisory Associates, LLC (“Donohoe Advisory”) in connection with its efforts to seek a listing for its common shares on a national securities exchange.

Donohoe Advisory was founded by Dave Donohoe in 2004, and since that time the firm has successfully represented hundreds of companies in a wide range of listing proceedings and engagements at both Nasdaq and the NYSE. Each professional member of Donohoe Advisory’s team previously worked for either The Nasdaq Stock Market (“Nasdaq”) or the New York Stock Exchange (the “NYSE”). Prior to forming Donohoe Advisory, Dave Donohoe spent 9+ years with Nasdaq, where he ultimately served as Chief Counsel in the Listing Qualifications Department.

Bradley Robinson, CEO, Predictive Technology Group, Inc. states, “At this juncture in PRED’s corporate growth, PRED believes it is well positioned to pursue a listing on a recognized exchange. Hiring Donohoe Advisory will help to further this effort.”

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED’s subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES COMPLETION OF GENOTYPING IN TWO CLINICAL TRIALS OF ARTGUIDE™

Salt Lake City, UT — February 20, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED) announces that Predictive Therapeutics, LLC, its wholly-owned subsidiary, completed a crucial milestone in the development and commercialization of ARTGuide™.

The Company’s scientific team completed the genotyping in two clinical trials of ARTGuide™. As such, Company representatives are providing three scientific presentations at the 65th Annual Meeting of the Society for Reproductive Investigation (SRI) on March 9th and 10th in San Diego, CA.

Predictive Therapeutics, LLC anticipates its launch of a novel test for women experiencing infertility, as a result of endometriosis and other health concerns, called ARTGuide™. The test is expected to change the way Advanced Reproductive Technologies (ART), such as In Vitro Fertilization (IVF), are used to help couples struggling to have a baby. After testing thousands of women as part of the development program, the Company now expects commercial launch of the ARTGuide™ infertility test in the United States during Q3 2018.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis and pelvic pain.

PRED and its subsidiaries remain leaders in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments.

About Endometriosis:

Endometriosis affects more than 10 million women in the United States. Endometriosis occurs when the tissue similar to the lining of the uterus (womb), found in other parts of the body -most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.

About Predictive Technology Group, Inc.:
Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Pelvic Pain, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

DOYEN ELEMENTS, INC. HIRES MR. DOUG GOOD FEATHER AS ITS CULTURAL AMBASSADOR

February 12, 2018- Colorado Springs, Colorado – Doyen Elements, Inc. in the USA announces that it has entered into an employment agreement with Doug Good Feather as Cultural Ambassador effective March 1, 2018.

Doug Good Feather – is a renowned International Native American Cultural Ambassador, fluent speaker of the Lakota language, Traditional Healing Consultant, Iraq War Veteran (2 tours), Stage and Screen Actor, Grammy Award Winning Lakota Singer, Scholar of Psychology and Counseling (’18), Public Speaker and Nation Builder.

Doug, a descendant of Sitting Bull, will be reporting to the CEO as an authorized representative of goodwill between the company and the indigenous people. He will define the sum of beliefs and common characteristics of a group of people and the broader society; including the aspects of language, customs and values. This will include fostering strong work cultures among businesses and marketing the humanitarian aspect of the company.

He travels the world doing workshops, speeches and media appearances as a professional speaker, trainer, consultant, writer and life coach. Good Feather has given over 1,000 presentations for corporations, associations, government agencies and nonprofit organizations over the last decade. Doug is the Executive Director of the Lakota Way Healing Center located in Denver, CO, which offers programs for healing and personal development. Doug has written articles, training programs, facilitates personal healing and growth seminars and is a sought-after professional for conference keynotes, radio shows, television shows and movies.

The focus of Doug’s work is on the development of treatments for PTSD, Drug and Alcohol Addictions, Suicide Prevention and Homelessness. This endeavor has taken him on many adventures through traditional and some not-so-traditional training programs. An important aspect of Doug’s presentations is that he addresses the psychological perspectives and principles behind the practical tools that he teaches. As a result, audiences are often entranced and excited about utilizing the traditional Native ways to heal in this modern age.

Doug’s business background ranges from executive director to counselor, public speaker, and traditional healing consultant. He works as a consultant and coach in the areas of healing and self-improvement. A leadership member of several non-profit organizations, he is active in charitable, environmental and civic organizations for the betterment of families and communities. Doug contributes to the growth of the organization by building bridges between indigenous nations and lifestyle communities and the economic development opportunities that the corporate venture has to offer those groups. This work requires a truly unique individual – a genuine, legitimate and credible person to speak with elder council members as well as lifestyle influencers alike. Doug Good Feather is highly experienced in this highly unique role working with these specific groups of people.

“We are excited and very fortunate to welcome Doug Good Feather to our team as we continue to expand the humanitarian aspect of our company,” says Jeff Hranicka, COO of Doyen Elements, Inc.

For more information about Doyen Elements, Inc. in the USA, please contact info@doyenelementsus.com or visit www.doyenelementsus.com. (855) DOYEN-US

About Doyen Elements Inc

Launched in October 2105, Doyen Elements Inc. a US company, began as a consultancy firm and has evolved to include a research and development vertical for Industrial Hemp. Its leadership team merges traditional business management with a team of scientists that focus on data collection and analysis of chemical, genetic and phenotypic profiles of hemp, allowing the company to create proprietary varieties of hemp that are targeted for specific uses for the emerging markets.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Forward Looking Statements:

This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state.

This Press Release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These “forward-looking statements” that address activities, events or developments that Doyen Elements, Inc. expects, anticipates, or estimates may occur in the future. Generally forward-looking statements by words such as “may,” “will,” “would,” “could,” “continue,” “potential,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend” and other similar expressions. There are a numerous risks and uncertainties, both known and unknown, that could cause actual results to differ materially from the results implied by the forward-looking statements, which may include but are not limited to, business risks, general industry conditions and competition, general economic factors, governmental actions, legislative conditions, the impact of cannabis industry regulation, legislation in the United States and internationally and technological advances. Doyen Elements undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) APPOINTS RONALD BARHORST TO CHAIR ITS FINANCIAL ADVISORY BOARD

Salt Lake City, UT — January 30, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that its Financial Advisory Board appointed Mr. Ronald Barhorst as Chairman. Mr. Barhorst brings in depth finance and governance experience gained during a career in the financial markets.

In January 2013, after 25 years in the financial services industry, Mr. Barhorst retired as President and CEO of ING Financial Advisers, LLC, Systematized Benefits Administrators, Inc., and ING Investment Advisors, LLC. Mr. Barhorst served as a director of ING Life Insurance Holding Company, Inc. and as an officer of several other ING companies. Mr. Barhorst currently serves as Chairman of the California State University Foundation Board of Governors, a position he has held for the past 15 years.

“I have had the opportunity to work with Predictive Technology Group or their predecessor companies for the past 8 years,” said Ronald Barhorst. “I am impressed with the brilliant minds that drive this Company and the substantial impact that this Company represents in targeted gene based therapeutics and women’s health.”

“As we move forward to becoming a full-reporting company under the Securities Exchange Act of 1934, Ron’s wealth of experience, gained in senior executive roles in the financial industry, will help ensure PRED maintains proper governance, oversight and guidance through its Board and Committees,” said Bradley Robinson, CEO of Predictive Technology Group.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.